Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

  • Rondy, Marc
  • Launay, Odile
  • Castilla Catalán, Jesús
  • Costanzo, Simona
  • Puig-Barberà, Joan
  • Gefenaite, Giedre
  • Larrauri, Amparo
  • Rizzo, Caterina
  • Pitigoi, Daniela
  • Syrjänen, Ritva K
  • Machado, Ausenda
  • Kurečić Filipović, Sanja
  • Horváth, Judit Krisztina
  • Paradowska-Stankiewicz, Iwona
  • Marbus, Sierk
  • Moren, Alain
  • InNHOVE/I-MOVE+working group
In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.
Repisalud
Publicación Artículo científico (JournalArticle)

Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18)

  • Kissling, Esther
  • Pozo Sanchez, Francisco
  • Buda, Silke
  • Vilcu, Ana-Maria
  • Rizzo, Caterina
  • Gherasim, Alin Manuel
  • Horváth, Judit Krisztina
  • Brytting, Mia
  • Domegan, Lisa
  • Meijer, Adam
  • Paradowska-Stankiewicz, Iwona
  • Machado, Ausenda
  • Vučina, Vesna Višekruna
  • Lazar, Mihaela
  • Johansen, Kari
  • Dürrwald, Ralf
  • van der Werf, Sylvie
  • Bella, Antonino
  • Larrauri, Amparo
  • Ferenczi, Annamária
  • Zakikhany, Katherina
  • O'Donnell, Joan
  • Dijkstra, Frederika
  • Bogusz, Joanna
  • Guiomar, Raquel
  • Valenciano, Marta
  • Filipović, Sanja Kurečić
  • Pitigoi, Daniela
  • Penttinen, Pasi
  • I-MOVE/I-MOVE+ study team
  • Mazagatos, Clara
  • Casas Flecha, Inmaculada
Influenza A(H3N2) viruses predominated in Europe in 2016-17. In 2017-18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017-18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016-17 and 2017-18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. During the 2017-18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47-69). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37-79), 50% (95% CI: 28-66) and 66% (95% CI: 42-80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17-38) in 2016-17 and 13% (95% CI: -15 to 34) in 2017-18. Among 0-14-year-olds VE against A(H3N2) was 28% (95%CI: -10 to 53) and 29% (95% CI: -87 to 73), among 15-64-year-olds 34% (95% CI: 18-46) and 33% (95% CI: -3 to 56) and among those aged ≥65 years 15% (95% CI: -10 to 34) and -9% (95% CI: -74 to 32) in 2016-17 and 2017-18, respectively. Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was <35% in 2016-17 and 2017-18. The egg propagation derived antigenic mismatch of the vaccine seed virus with circulating strains may have contributed to this low effectiveness. A(H3N2) seed viruses for vaccines in subsequent seasons may be subject to the same adaptations; in years with lower than expected VE, recommendations of preventive measures other than vaccination should be given in a timely manner.
Repisalud
Publicación Artículo científico (JournalArticle)

Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis

  • Castilla Catalán, Jesús
  • Navascués, Ana
  • Casado, Itziar
  • Díaz-González, Jorge
  • Pérez-García, Alejandra
  • Fernandino, Leticia
  • Martínez-Baz, Iván
  • Aguinaga, Aitziber
  • Pozo Sanchez, Francisco
  • Ezpeleta, Carmen
The 2016/17 mid-season vaccine effectiveness estimate against influenza A(H3N2) was 15% (95% confidence interval: -11 to 35) in Navarre. Comparing to individuals unvaccinated in the current and four prior seasons, effectiveness was 24% for current and 3-4 prior doses, 61% for current and 1-2 prior doses, 42% for only current vaccination, and 58% for 3-4 prior doses. This suggests moderate effectiveness for different combinations of vaccination in the current and prior seasons.
Repisalud
Publicación Artículo científico (JournalArticle)

Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis

  • Sandmann, Frank G
  • van Leeuwen, Edwin
  • Bernard-Stoecklin, Sibylle
  • Casado, Itziar
  • Castilla Catalán, Jesús
  • Domegan, Lisa
  • Gherasim, Alin Manuel
  • Hooiveld, Mariëtte
  • Kislaya, Irina
  • Larrauri, Amparo
  • Levy-Bruhl, Daniel
  • Machado, Ausenda
  • Marques, Diogo FP
  • Martínez-Baz, Iván
  • Mazagatos, Clara
  • McMenamin, Jim
  • Meijer, Adam
  • Murray, Josephine-L K
  • Nunes, Baltazar
  • O'Donnell, Joan
  • Reynolds, Arlene
  • Thorrington, Dominic
  • Pebody, Richard
  • Baguelin, Marc
Introduction: Despite seasonal influenza vaccination programmes in most countries targeting individuals aged ≥ 65 (or ≥ 55) years and high risk-groups, significant disease burden remains. We explored the impact and cost-effectiveness of 27 vaccination programmes targeting the elderly and/or children in eight European settings (n = 205.8 million). Methods: We used an age-structured dynamic-transmission model to infer age- and (sub-)type-specific seasonal influenza virus infections calibrated to England, France, Ireland, Navarra, The Netherlands, Portugal, Scotland, and Spain between 2010/11 and 2017/18. The base-case vaccination scenario consisted of non-adjuvanted, non-high dose trivalent vaccines (TV) and no universal paediatric vaccination. We explored i) moving the elderly to "improved" (i.e., adjuvanted or high-dose) trivalent vaccines (iTV) or non-adjuvanted non-high-dose quadrivalent vaccines (QV); ii) adopting mass paediatric vaccination with TV or QV; and iii) combining the elderly and paediatric strategies. We estimated setting-specific costs and quality-adjusted life years (QALYs) gained from the healthcare perspective, and discounted QALYs at 3.0%. Results: In the elderly, the estimated numbers of infection per 100,000 population are reduced by a median of 261.5 (range across settings: 154.4, 475.7) when moving the elderly to iTV and by 150.8 (77.6, 262.3) when moving them to QV. Through indirect protection, adopting mass paediatric programmes with 25% uptake achieves similar reductions in the elderly of 233.6 using TV (range: 58.9, 425.6) or 266.5 using QV (65.7, 477.9), with substantial health gains from averted infections across ages. At €35,000/QALY gained, moving the elderly to iTV plus adopting mass paediatric QV programmes provides the highest mean net benefits and probabilities of being cost-effective in all settings and paediatric coverage levels. Conclusion: Given the direct and indirect protection, and depending on the vaccine prices, model results support a combination of having moved the elderly to an improved vaccine and adopting universal paediatric vaccination programmes across the European settings.
Repisalud
Publicación Artículo científico (JournalArticle)

Impact of Influenza Vaccination on the Burden of Severe Influenza in the Elderly: Spain, 2017-2020

  • Mazagatos, Clara
  • Delgado-Sanz, Concepcion
  • Milagro, Ana
  • Liébana-Rodríguez, María
  • Larrauri, Amparo
Annual influenza vaccination is the main strategy to reduce the burden of seasonal influenza epidemics and is recommended for the elderly in most countries with influenza vaccination strategies, with the main objective of preventing hospitalizations and mortality associated with seasonal influenza in this age group. Studies from different countries have estimated the benefits of seasonal influenza vaccination programs in the elderly, preventing a considerable number of cases, hospitalizations and deaths every year. A study measured the number of medically attended confirmed influenza cases in primary care that are prevented annually by vaccination in the population aged 65 and older in Spain, the Netherlands and Portugal, but estimates of the impact of the national influenza vaccination program in the prevention of severe disease in Spain are lacking. The two objectives of this study were to estimate the burden of severe influenza disease in the Spanish population and to measure the impact of influenza vaccination in the prevention of these outcomes in the population aged 65 years and older. Using influenza surveillance systems put in place before the COVID-19 pandemic, we conducted a retrospective observational study to estimate the burden of hospitalizations and ICU admissions in Spain between 2017-18 and 2019-20, by season and age group. Burden estimates for the 65+ group, combined with vaccine effectiveness (VE) and vaccination coverage (VC) data, were used as input data in an ecological, observational study to estimate the impact of the influenza vaccination program on the elderly. We found a higher burden of severe influenza disease in seasons 2017-18 and 2018-19, with A(H3N2) circulation, and in the youngest and oldest age groups. In those aged 65 and older, we estimated an average of 9900 influenza hospitalizations and 1541 ICU admissions averted by vaccination each year. Seasonal influenza vaccination was able to prevent between 11 and 26% influenza hospitalizations and around 40% ICU admissions in the elderly in the three pre-pandemic seasons. In conclusion, our study complements previous analyses in the primary care setting in Spain and demonstrates the benefits of the annual influenza vaccination program in the prevention of severe influenza disease in the elderly, even in seasons with moderate VE.
Repisalud
Publicación Artículo científico (JournalArticle)

Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population

  • Machado, Ausenda
  • Kislaya, Irina
  • Larrauri, Amparo
  • Matias Dias, Carlos
  • Nunes, Baltazar
Background: All aged individuals with a chronic condition and those with 65 and more years are at increased risk of severe influenza post-infection complications. There is limited research on cases averted by the yearly vaccination programs in high-risk individuals. The objective was to estimate the impact of trivalent seasonal influenza vaccination on averted hospitalizations and death among the high-risk population in Portugal. Methods: The impact of trivalent seasonal influenza vaccination was estimated using vaccine coverage, vaccine effectiveness and the number of influenza-related hospitalizations and deaths. The number of averted events (NAE), prevented fraction (PF) and number needed to vaccinate (NVN) were estimated for seasons 2014/15 to 2016/17. Results: The vaccination strategy averted on average approximately 1833 hospitalizations and 383 deaths per season. Highest NAE was observed in the ≥65 years population (85% of hospitalizations and 95% deaths) and in the 2016/17 season (1957 hospitalizations and 439 deaths). On average, seasonal vaccination prevented 21% of hospitalizations in the population aged 65 and more, and 18.5% in the population with chronic conditions. The vaccination also prevented 29% and 19.5% of deaths in each group of the high-risk population. It would be needed to vaccinate 3360 high-risk individuals, to prevent one hospitalization and 60,471 high-risk individuals to prevent one death. Conclusion: The yearly influenza vaccination campaigns had a sustained positive benefit for the high-risk population, reducing hospitalizations and deaths. These results can support public health plans toward increased vaccine coverage in high-risk groups.
Repisalud
Publicación Artículo científico (JournalArticle)

Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain

  • Gherasim, Alin Manuel
  • Martínez-Baz, Iván
  • Castilla Catalán, Jesús
  • Pozo Sanchez, Francisco
  • Larrauri, Amparo
  • cycEVA working group
  • Jimenez-Jorge, Silvia
  • Mateo-Ontañon, Salvador de
  • Delgado-Sanz, Concepcion
  • Oliva Dominguez, Jesus Angel
  • Savulescu, Camelia
  • Casas Flecha, Inmaculada
  • Garcia-Cenoz, Manuel
BACKGROUND: Recent studies suggest that the protective effect of the current influenza vaccine could be influenced by vaccination in previous seasons. We estimated the combined effect of the previous and current influenza vaccines from the 2010-2011 season to the 2015-2016 season in Spain. METHODS: We performed a test-negative case-control study in patients ≥9 years old. We estimated the influenza vaccine effectiveness (IVE) against influenza A(H1N1)pdm09, A(H3N2), and B virus. RESULTS: We included 1206 influenza A(H1N1)pdm09 cases, 1358 A(H3N2) cases and 1079 B cases. IVE against A(H1N1)pdm09 virus in the pooled-season analysis was 53% (95% Confidence Interval (CI): 21% to 72%) for those vaccinated only in the current season and 50% (95%CI: 23% to 68%) for those vaccinated in the both current and previous seasons. Against the influenza A(H3N2) virus, IVE was 17% (95%CI: -43% to 52%) for those vaccinated only in the current season and 3% (95%CI: -33% to 28%) for those vaccinated in both seasons. Regarding influenza B, we obtained similar IVEs for those vaccinated only in the current and those vaccinated in both seasons: 57% (95%CI: 12% to 79%) and 56% (95%CI: 36% to 70%), respectively. CONCLUSION: Our results suggested no interference between the previous and current influenza vaccines against A(H1N1)pdm09 and B viruses, but a possible negative interference against A(H3N2) virus.
Repisalud
Publicación Artículo científico (JournalArticle)

Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine

  • Rose, Angela Mc
  • Kissling, Esther
  • Gherasim, Alin Manuel
  • Casado, Itziar
  • Bella, Antonino
  • Launay, Odile
  • Lazar, Mihaela
  • Marbus, Sierk
  • Kuliešė, Monika
  • Syrjänen, Ritva
  • Machado, Ausenda
  • Kurečić Filipović, Sanja
  • Larrauri, Amparo
  • Castilla Catalán, Jesús
  • Alfonsi, Valeria
  • Galtier, Florence
  • Ivanciuc, Alina
  • Meijer, Adam
  • Mickiene, Aukse
  • Ikonen, Niina
  • Gomez, Verónica
  • Lovrić Makarić, Zvjezdana
  • Moren, Alain
  • Valenciano, Marta
Background: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe. Methods: Following the same generic protocol for test-negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. "Vaccinated" patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions. Results: We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65- to 79-year-olds and 14% (95% CI: -22 to 39) in ≥80-year-olds. Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65- to 79-year-olds and 19% (95% CI: -7 to 38) in ≥80-year-olds. Conclusions: IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza.
Repisalud
Publicación Artículo científico (JournalArticle)

Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons.

  • Machado, Ausenda
  • Mazagatos, Clara
  • Dijkstra, Frederika
  • Kislaya, Irina
  • Gherasim, Alin Manuel
  • McDonald, Scott A
  • Kissling, Esther
  • Valenciano, Marta
  • Meijer, Adam
  • Hooiveld, Mariëtte
  • Nunes, Baltazar
  • Larrauri, Amparo
Background: To increase the acceptability of influenza vaccine, it is important to quantify the overall benefits of the vaccination programme. Aim: To assess the impact of influenza vaccination in Portugal, Spain and the Netherlands, we estimated the number of medically attended influenza-confirmed cases (MAICC) in primary care averted in the seasons 2015/16 to 2017/18 among those ≥ 65 years. Methods: We used an ecological approach to estimate vaccination impact. We compared the number of observed MAICC (n) to the estimated number that would have occurred without the vaccination programme (N). To estimate N, we used: (i) MAICC estimated from influenza surveillance systems, (ii) vaccine coverage, (iii) pooled (sub)type-specific influenza vaccine effectiveness estimates for seasons 2015/16 to 2017/18, weighted by the proportion of virus circulation in each season and country. We estimated the number of MAICC averted (NAE) and the prevented fraction (PF) by the vaccination programme. Results: The annual average of NAE in the population ≥ 65 years was 33, 58 and 204 MAICC per 100,000 in Portugal, Spain and the Netherlands, respectively. On average, influenza vaccination prevented 10.7%, 10.9% and 14.2% of potential influenza MAICC each season in these countries. The lowest PF was in 2016/17 (4.9-6.1%) with an NAE ranging from 24 to 69 per 100,000. Conclusions: Our results suggest that influenza vaccination programmes reduced a substantial number of MAICC. Together with studies on hospitalisations and deaths averted by influenza vaccination programmes, this will contribute to the evaluation of the impact of vaccination strategies and strengthen public health communication.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.

  • Hanquet, Germaine
  • Krizova, Pavla
  • Valentiner-Branth, Palle
  • Ladhani, Shamez N.
  • Nuorti, J. Pekka
  • Lepoutre, Agnes
  • Mereckiene, Jolita
  • Knol, Mirjam
  • Winje, Brita A.
  • Ciruela, Pilar
  • Ordobas, Maria
  • Guevara, Marcela
  • McDonald, Eisin
  • Morfeldt, Eva
  • Kozakova, Jana
  • Slotved, Hans-Christian
  • Fry, Norman K.
  • Rinta-Kokko, Hanna
  • Varon, Emmanuelle
  • Corcoran, Mary
  • Van der Ende, Arie
  • Vestrheim, Didrik F.
  • Muñoz-Almagro, Carmen
  • Latasa, Pello
  • Castilla, Jesús
  • Smith, Andrew
  • Henriques-Normark, Birgitta
  • Whittaker, Robert
  • Pastore Celentano, Lucia
  • Savulescu, Camelia
  • SpIDnet/I-MOVE+ Pneumo Group
Background: pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. Methods: for each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 - IRR)*100. Results: after five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI -4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI -8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. Conclusion: overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.

  • Hanquet, Germaine
  • Krizova, Pavla
  • Valentiner-Branth, Palle
  • Ladhani, Shamez N.
  • Nuorti, J. Pekka
  • Lepoutre, Agnes
  • Mereckiene, Jolita
  • Knol, Mirjam
  • Winje, Brita A.
  • Ciruela, Pilar
  • Ordobas, Maria
  • Guevara, Marcela
  • McDonald, Eisin
  • Morfeldt, Eva
  • Kozakova, Jana
  • Slotved, Hans-Christian
  • Fry, Norman K.
  • Rinta-Kokko, Hanna
  • Varon, Emmanuelle
  • Corcoran, Mary
  • Van der Ende, Arie
  • Vestrheim, Didrik F.
  • Muñoz-Almagro, Carmen
  • Latasa, Pello
  • Castilla, Jesús
  • Smith, Andrew
  • Henriques-Normark, Birgitta
  • Whittaker, Robert
  • Pastore Celentano, Lucia
  • Savulescu, Camelia
  • SpIDnet/I-MOVE+ Pneumo Group
Background: pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. Methods: for each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 - IRR)*100. Results: after five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI -4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI -8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. Conclusion: overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative.